Cargando…

Case report: application of pharmacogenetics in the personalized treatment of an elderly patient with a major depressive episode

BACKGROUND: Pharmacogenetic analyses can predict interpersonal differences in response to psychopharmacotherapy, which greatly facilitates the selection of the most effective medication at optimal doses. By personalizing therapy in this way, we can minimize adverse drug reactions (ADR) and prevent p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pjevac, Milica, Redenšek Trampuž, Sara, Blagus, Tanja, Dolžan, Vita, Bon, Jurij
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440381/ https://www.ncbi.nlm.nih.gov/pubmed/37608991 http://dx.doi.org/10.3389/fpsyt.2023.1250253

Ejemplares similares

Serotonin-Related Functional Genetic Variants Affect the Occurrence of Psychiatric and Motor Adverse Events of Dopaminergic Treatment in Parkinson’s Disease: A Retrospective Cohort Study
por: Redenšek, Sara, et al.
Publicado: (2022)

Genetic Variability of the Vitamin D Receptor Affects Susceptibility to Parkinson’s Disease and Dopaminergic Treatment Adverse Events
por: Redenšek, Sara, et al.
Publicado: (2022)

Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson’s Disease
por: Redenšek, Sara, et al.
Publicado: (2019)

Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson’s Disease
por: Redenšek, Sara, et al.
Publicado: (2020)

The role of pharmacogenetics in the treatment of major depressive disorder: a critical review
por: Barlati, Stefano, et al.
Publicado: (2023)

Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature
por: Redenšek Trampuž, Sara, et al.
Publicado: (2023)

From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms
por: Redenšek, Sara, et al.
Publicado: (2018)

Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma
por: Goričar, Katja, et al.
Publicado: (2017)

Investigation of Paraoxonase-1 Genotype and Enzyme-Kinetic Parameters in the Context of Cognitive Impairment in Parkinson’s Disease
por: Petrič, Boštjan, et al.
Publicado: (2023)

Molecular Mechanisms Related to Responses to Oxidative Stress and Antioxidative Therapies in COVID-19: A Systematic Review
por: Tsermpini, Evangelia Eirini, et al.
Publicado: (2022)

Nanoscale Bilirubin Analysis in Translational Research and Precision Medicine by the Recombinant Protein HUG
por: Sist, Paola, et al.
Publicado: (2023)

Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease
por: Redenšek, Sara, et al.
Publicado: (2019)

Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect?
por: Redenšek, Sara, et al.
Publicado: (2017)

A case report—“When less is more”: controlled inpatient reduction of anticholinergic burden in a patient with clozapine-resistant schizophrenia
por: Pjevac, Milica, et al.
Publicado: (2023)

Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies
por: Tsermpini, Evangelia Eirini, et al.
Publicado: (2022)

Abnormalities in Electroencephalographic Microstates Among Adolescents With First Episode Major Depressive Disorder
por: He, Yuqiong, et al.
Publicado: (2021)

First-Episode Patients Report Cognitive Difficulties in Executive Functioning 1 Year After Initial Episode of Major Depressive Disorder
por: Schmid, Marit, et al.
Publicado: (2021)

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest
por: Xiong, Shihong, et al.
Publicado: (2022)

Alternations of White Matter Structural Networks in First Episode Untreated Major Depressive Disorder with Short Duration
por: Lu, Yi, et al.
Publicado: (2017)

Desynchronized white matter function and structure in drug-naive first-episode major depressive disorder patients
por: Guo, Qinger, et al.
Publicado: (2023)

Volumetric assessment of individual thalamic nuclei in patients with drug-naïve, first-episode major depressive disorder
por: Chibaatar, Enkhmurun, et al.
Publicado: (2023)

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease
por: Redenšek, Sara, et al.
Publicado: (2019)

Early Effects of Repetitive Transcranial Magnetic Stimulation Combined With Sertraline in Adolescents With First-Episode Major Depressive Disorder
por: Chen, Haisi, et al.
Publicado: (2022)

Association of Subclinical Hypothyroidism With Anxiety Symptom in Young First-Episode and Drug-Naïve Patients With Major Depressive Disorder
por: Yang, Ruchang, et al.
Publicado: (2022)

Prospective study on Maresin-1 and cytokine levels in medication-naïve adolescents with first-episode major depressive disorder
por: Qiu, Tian, et al.
Publicado: (2023)

Adjunctive repetitive transcranial magnetic stimulation for adolescents with first-episode major depressive disorder: a meta-analysis
por: Sun, Chen-Hui, et al.
Publicado: (2023)

Abnormal dynamic functional connectivity of thalamic subregions in patients with first-episode, drug-naïve major depressive disorder
por: Zheng, Yanting, et al.
Publicado: (2023)

Experiences of seeking and accessing medical care among persons with major depression: A qualitative descriptive study of persons with depression in China
por: Zhou, Yan Hua, et al.
Publicado: (2023)

Subcortical Brain Volumes Relate to Neurocognition in First-Episode Schizophrenia, Bipolar Disorder, Major Depression Disorder, and Healthy Controls
por: Shi, Jing, et al.
Publicado: (2022)

Volumetric Deficit Within the Fronto-Limbic-Striatal Circuit in First-Episode Drug Naïve Patients With Major Depression Disorder
por: Zhang, Yiran, et al.
Publicado: (2021)

Reduced Brain Gray Matter Volume in Patients With First-Episode Major Depressive Disorder: A Quantitative Meta-Analysis
por: Zheng, Ruiping, et al.
Publicado: (2021)

Association of thyroid function with abnormal lipid metabolism in young patients with first-episode and drug naïve major depressive disorder
por: Hu, Jieqiong, et al.
Publicado: (2023)

Co-expression network of mRNA and DNA methylation in first-episode and drug-naive adolescents with major depressive disorder
por: Tao, Yuanmei, et al.
Publicado: (2023)

Association between triglyceride glucose index and suicide attempts in patients with first-episode drug-naïve major depressive disorder
por: Liu, Junjun, et al.
Publicado: (2023)

Thyroid dysfunction in young, first-episode and drug-naïve patients with major depressive disorder: prevalence and associated clinical factors
por: Wu, Jinbo, et al.
Publicado: (2023)

Association of Genetic Polymorphisms in Oxidative Stress and Inflammation Pathways with Glaucoma Risk and Phenotype
por: Atanasovska Velkovska, Makedonka, et al.
Publicado: (2021)

Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinson’s Disease
por: Levstek, Tina, et al.
Publicado: (2021)

Associations Among Monoamine Neurotransmitter Pathways, Personality Traits, and Major Depressive Disorder
por: Shao, Xiaojun, et al.
Publicado: (2020)

Association of Lipid Profile and Suicide Attempts in a Large Sample of First Episode Drug-Naive Patients With Major Depressive Disorder
por: Ma, Yue-Jiao, et al.
Publicado: (2020)

Dysfunction of Pre-Attentive Visual Information Processing in Drug-Naïve Women, But Not Men, During the Initial Episode of Major Depressive Disorder
por: Yang, Xiuxian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1dc304mh1047pf2i21lkcsb5i3